Barclays Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $16.00

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its target price decreased by stock analysts at Barclays from $19.00 to $16.00 in a research report issued on Monday,Benzinga reports. The firm presently has an "equal weight" rating on the stock. Barclays's target price indicates a potential upside of 34.85% from the stock's current price.

Several other research firms have also recently weighed in on BLCO. Bank of America cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a report on Thursday, February 20th. Evercore ISI decreased their target price on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company decreased their price target on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. Citigroup dropped their price objective on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a report on Thursday, April 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Bausch + Lomb has a consensus rating of "Hold" and an average target price of $15.54.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO traded up $0.17 during midday trading on Monday, hitting $11.87. 343,253 shares of the company's stock were exchanged, compared to its average volume of 677,290. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $21.69. The firm has a market cap of $4.19 billion, a P/E ratio of -13.04, a PEG ratio of 0.85 and a beta of 0.56. The stock's 50 day moving average price is $11.92 and its 200-day moving average price is $15.36. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). The business had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. Bausch + Lomb's revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 earnings per share. Equities research analysts anticipate that Bausch + Lomb will post 0.74 EPS for the current year.

Insider Transactions at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders acquired 22,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were bought at an average cost of $11.28 per share, with a total value of $248,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 719,156 shares in the company, valued at $8,112,079.68. This represents a 3.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.76% of the company's stock.

Institutional Trading of Bausch + Lomb

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. boosted its holdings in Bausch + Lomb by 68.3% during the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after buying an additional 1,004 shares in the last quarter. National Bank of Canada FI lifted its stake in Bausch + Lomb by 101.7% during the first quarter. National Bank of Canada FI now owns 6,719 shares of the company's stock worth $97,000 after purchasing an additional 3,387 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in Bausch + Lomb during the 4th quarter worth about $181,000. Alpine Global Management LLC acquired a new position in Bausch + Lomb in the 4th quarter valued at about $181,000. Finally, Covestor Ltd purchased a new stake in Bausch + Lomb during the fourth quarter worth about $188,000. Institutional investors own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.